
Human Recombinant CD32C 13Gln Stable Cell Line
Cat. No. M00601**Version 04282015**

I. INTRODUCTION

Catalog Number: M00601

Cell Line Name: CHO-K1/human CD32C 13Gln

Gene Synonyms: CD32; FCG2; CD32C; CDW32; IGFR2; FCRIIC

Expressed Gene: Codon Optimized from U90938.1; no expressed tags

Host Cell: CHO-K1

Quantity: Two vials of frozen cells (1×10^6 per vial)

Stability: 15 passages

Application: Binding assay or use as immunogen

Freeze Medium: 95% complete growth medium, 5% DMSO

Complete Growth Medium: F12K, 10% FBS

Culture Medium: F12K, 10% FBS, 8 μ g/ml PuromycinMycoplasma Status[§]: Negative

Storage: Liquid nitrogen immediately upon receipt

II. BACKGROUND

Human studies suggest expression of CD32C could help predict patient responses to vaccines. CD32C normally contains a termination codon, but 7%–15% of individuals carry a mutation that changes it into a full-length open reading frame. Individuals with this variant expressed CD32C on B cells were more likely to respond to an anthrax vaccine than patients that did not express the variant. Individuals with the full-length CD32C variant also were more likely to develop the autoimmune disease systemic lupus erythematosus (SLE) than those without the variant.

[§]: GenScript employs a PCR-based method to test the mycoplasma. The test covers 11 of the most common strains of mycoplasma, (covering approximately 95% of *M. fermentans*, *M. hyorhinis*, *M. arginini*, *M. orale*, *M. salivarium*, *M. hominis*, *M. pulmonis*, *M. arthritis*, *M. neurolyticum*, *M. hyopneumoniae* and *M. capricolum*) and one species *Ureaplasma* (*U. urealyticum*), with sufficient sensitivity and specificity.

III. REPRESENTATIVE DATA

- Protein Expression Validation




Figure 1. FACS analysis of human CD32C 13Gln expression in CHO-K1 cells.

IV. THAWING AND SUBCULTURING

Thawing Protocol

1. Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
2. Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
3. Pellet cells by centrifugation at 200 x g for 5 min, and remove the medium.
4. Resuspend the cells in complete growth medium.
5. Transfer the cell suspension to a 10 cm dish with 10 ml of complete growth medium.
6. Grow the cells incubator with 37°C, 5 %CO₂.
7. Add antibiotic in the following day.

Sub-culturing Protocol

1. Remove the culture medium from cells.
2. Wash cells with PBS (pH=7.4) to remove all traces of serum that contains trypsin inhibitor.
3. Add 2.0 ml of 0.25% (w/v) Trypsin- EDTA (GIBCO, Cat No. 25200-072) solution into 10 cm dish and observe the cells under an inverted microscope until cell layer is dispersed (usually within 3 to 5 minutes).
Note: To avoid cells clumping, do not agitate the cells by hitting or shaking the dish while waiting for the cells detach. If cells are difficult to detach, please place the dish in 37°C incubator for ~2 min.
4. Add 6.0 to 8.0 ml of complete growth medium into dish and aspirate cells by gently pipetting.
5. Centrifuge the cells at 200 x g for 5 min, and remove the medium.
6. Resuspend the cells in culture medium and add the cells suspension to new culture dish.
7. Grow the cells in incubator with 37°C, 5% CO₂.

Subcultivation Ratio: 1:3 to 1:8 weekly.

Medium Renewal: Every 2 to 3 days

V. REFERENCES

1. Li, X. et al. Allelic-Dependent Expression of an Activating Fc Receptor on B Cells Enhances Humoral Immune Responses [J]. Science Translational Medicine, 2013, (5): 175 - 216.

GenScript USA Inc,

860 Centennial Ave.

Piscataway, NJ 08854

Toll-Free: 1-877-436-7274

Tel: 1-732-885-9188, Fax: 1-732-210-0262

Email: product@genscript.com

Web: <http://www.genscript.com>

For Research Use Only.

860 Centennial Ave., Piscataway, NJ 08854, USA

Toll-Free: 1-877-436-7274 Tel: 1-732-885-9188 Fax: 1-732-210-0262 Email: product@genscript.com Web: www.genscript.com

Limited Use License Agreement

This is a legal agreement between you (Licensee) and GenScript USA Inc. governing use of GenScript's stable cell line products and protocols provided to licensee. By purchasing and using the stable cell line, the buyer agrees to comply with the following terms and conditions of this label license and recognizes and agrees to such restrictions:

- 1) The products are not transferable and will be used at the site where they were purchased. Transfer to another site owned by buyer will be permitted only upon written request by buyer followed by subsequent written approval by GenScript.
- 2) The purchaser cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party.
- 3) The products sold by GenScript are for laboratory and animal research purposes only. The products are not to be used on humans, for consumption, or for any unlawful uses.

GenScript USA Inc. will not assert against the buyer a claim of infringement of patents owned or controlled by GenScript USA Inc. and claiming this product based upon the manufacture, use or sale of a clinical diagnostic, therapeutic and vaccine, or prophylactic product developed in research by the buyer in which this product or its components has been employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on the use of this product for other purposes, contact Marketing Department, GenScript USA Inc., 120 Centennial Avenue, Piscataway, New Jersey 08840, U.S.A. Phone: 1-732-885-9188. Fax: 1-732-210-0262. Email: marketing@genscript.com.